Crispr Therapeutics AG (NASDAQ:CRSP) President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of CRSP stock opened at $65.36 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics AG has a fifty-two week low of $22.22 and a fifty-two week high of $74.00. The company has a market cap of $3.61 billion, a PE ratio of -19.00 and a beta of 3.31. The stock’s fifty day moving average price is $58.93 and its two-hundred day moving average price is $48.44.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. On average, equities analysts predict that Crispr Therapeutics AG will post 0.65 EPS for the current fiscal year.
A number of research firms recently commented on CRSP. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Piper Jaffray Companies restated a “buy” rating and issued a $104.00 price target on shares of Crispr Therapeutics in a report on Tuesday, November 26th. Roth Capital increased their price target on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Finally, Goldman Sachs Group upped their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the stock. Crispr Therapeutics has a consensus rating of “Buy” and a consensus target price of $69.54.
Several institutional investors have recently bought and sold shares of the company. Xact Kapitalforvaltning AB bought a new position in Crispr Therapeutics during the 2nd quarter valued at about $207,000. Commonwealth Equity Services LLC boosted its position in Crispr Therapeutics by 5.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock valued at $839,000 after buying an additional 986 shares during the period. Buckley Wealth Management LLC purchased a new stake in Crispr Therapeutics in the 2nd quarter valued at about $236,000. Carnegie Capital Asset Management LLC purchased a new stake in Crispr Therapeutics in the 2nd quarter valued at about $1,064,000. Finally, Moody Aldrich Partners LLC purchased a new stake in Crispr Therapeutics in the 2nd quarter valued at about $1,838,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Buy Rating
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.